Kaiyuan Securities: The pharmaceutical industry is gradually transitioning from old to new growth drivers, with innovation leading to breakthroughs across multiple fronts.

Chemical pharmaceuticals and biologics: Differentiated pipelines continue to emerge, overseas expansion is accelerating, and collaboration models are becoming increasingly diverse, driving sustained growth in the innovative drug industry.

Zhitong FinanceMay 22 10:15

Yaokang Biotech (688046): Market demand rebounds, core business develops steadily

Event Overview: In April 2026, Yaokang Bio released its 2025 annual report and Q1 2026 earnings report. The company achieved operating revenue of 793 million yuan in 2025, representing a year-on-year increase of 15.51%, and reported a net profit attributable to shareholders of 140 million yuan.

Huaan SecuritiesMay 18 13:17

Pharmakon Bio (688046): Revenue shows improvement trend, efficacy business contributes to performance elasticity.

Event Summary (1) Company Announcement 2025 Annual Report: In 2025, the company achieved operating revenue of 793 million yuan, representing a year-on-year increase of 15.51%; net profit attributable to shareholders reached 143 million yuan, up 29.88% year-on-year; non-recurring net

Huaxi SecuritiesMay 16 00:00

Pharmaceutical Health Biotech (688046): International expansion and new business initiatives are gradually paying off, with profits expected to accelerate.

The improvement in industry prosperity has led to a continued expansion in the demand for innovative models. Ongoing advancements in global new drug research and development have driven up the demand for experimental animal mouse models. This increased demand is not only reflected in the growth of quantity but, more importantly, in the rising need for high value-added innovative models.

Huayuan SecuritiesMay 13 19:12

Yaokang Bio (688046.SH): Appointment of Liu Yekun as Chief Financial Officer

Gelonghui, May 13th: Yaokang Bio (688046.SH) announced that the company recently received a written resignation report from its Secretary of the Board of Directors and Chief Financial Officer, Mr. Wang Yiou. In order to comply with the requirements of the 'Regulatory Rules for Secretaries of the Board of Listed Companies,' he has applied to resign from his position as Chief Financial Officer but will continue to serve as the Secretary of the Board of Directors after his resignation. On May 12, 2026, the company convened the 18th meeting of the Second Board of Directors, where it reviewed and approved the proposal on the appointment of the Chief Financial Officer. Upon nomination by the General Manager and following qualification reviews by the Nomination Committee and Audit Committee of the Board of Directors, the board agreed to appoint

Gelonghui FinanceMay 13 16:59

A-share market movement | Strong earnings from leading companies drive a collective rise in CRO concept stocks, with Kailaiying and Wuxi Apptec hitting the daily price limit.

Gelonghui, April 28 | The performance of leading companies in the sector was remarkable, with the CRO sector in the A-share market collectively rising. Among them, Kailaiying and Wuxi Apptec hit a 10CM limit-up, Yaokang Bio-tech rose over 4%, and Canbridge Pharma and Pharmablock rose over 3%. Last night, Wuxi Apptec announced its results, showing that the Q1 2026 performance exceeded expectations across the board. Revenue for the first quarter reached RMB 12.44 billion, a year-on-year increase of 28.8%, surpassing expectations while setting a new high for the same period in history and marking the company's first time breaking through the RMB 10 billion revenue threshold in Q1. Net profit attributable to shareholders was RMB 4.65 billion, an increase of 26.7% year-on-year; non-GAAP net profit attributable to shareholders was RMB 4.28 billion.

Gelonghui FinanceApr 28 10:31